The role of estrogen receptor beta (ERbeta) in malignant diseases--a new potential target for antiproliferative drugs in prevention and treatment of cancer.

Jan-Ake Gustafsson, Margaret Warner

Journal: Biochemical and biophysical research communications 2010;396(1):63-6

PMID: 20494112

Full Text on Elsevier Science View on PubMed

Abstract

The discovery of ERbeta in the middle of the 1990s represents a paradigm shift in our understanding of estrogen signaling. It has turned out that estrogen action is not mediated by one receptor, ERalpha, but by two balancing factors, ERalpha and ERbeta, which are often antagonistic to one another. Excitingly, ERbeta has been shown to be widespread in the body and to be involved in a multitude of physiological and pathophysiological events. This has led to a strong interest of the pharmaceutical industry to target ERbeta by drugs against various diseases. In this review, focus is on the role of ERbeta in malignant diseases where the anti proliferative activity of ERbeta gives hope of new therapeutic approaches.

Address: Center for BioSciences, Department of BioSciences and Nutrition, Karolinska Institutet, Stockholm, Sweden.

DOI: 10.1016/j.bbrc.2010.02.144

Link outs

Free resources

Medical:

https://medlineplus.gov/prostatecancer.html

Molecular Biology Databases:

https://www.informatics.jax.org/reference/20494112

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S0006...

MeSH Terms: Antineoplastic Agents, Breast, Breast Neoplasms, Cell Proliferation, Estrogen Receptor beta, Female, Hormone Replacement Therapy, Humans, Immunologic Surveillance, Male, Prostatic Neoplasms